Is CD133 a biomarker for cancer stem cells of colorectal cancer and brain tumors? A meta-analysis

International Journal of Biological Markers

Volumn 26, Issue 3, 2011, Pages 173-180

  Yang, Kun ^a   Chen, Xin Zu ^a   Zhang, Bo ^a   Yang, Chen ^a   Chen, Hai Ning ^a   Chen, Zhi Xin ^a   Zhou, Zong Guang ^a   Chen, Jia Ping ^a   Hu, Jian Kun ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Cancer stem cells (CSCs); CD133; In vitro tests; In vivo tests; Meta analysis; Statistics

Indexed keywords

BIOLOGICAL MARKER; CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ARTICLE; BRAIN TUMOR; CANCER RISK; CANCER STEM CELL; COLORECTAL CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INJECTION SITE; NONHUMAN; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TUMOR XENOGRAFT; COLORECTAL TUMOR; IMMUNOLOGY; META ANALYSIS; METABOLISM; PATHOLOGY;

ANTIGENS, CD; BRAIN NEOPLASMS; COLORECTAL NEOPLASMS; GLYCOPROTEINS; HUMANS; IN VITRO TECHNIQUES; NEOPLASTIC STEM CELLS; PEPTIDES;

EID: 80053347964     PISSN: 03936155     EISSN: None     Source Type: Journal    
DOI: 10.5301/JBM.2011.8551     Document Type: Article

References (65)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49.
2. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science 1977; 197: 461-3.
3. Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003; 3: 895-902.
4. Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. Cancer Res 2006; 66: 4553-7.
5. Soltysova A, Altanerova V, Altaner C. Cancer stem cells. Neoplasma 2005; 52: 435-40.
6. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003; 100: 3983-8.
7. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
8. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65: 10946-51.
9. Bonnet D, Dick J. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997; 3: 730-7.
10. Kim CF, Jackson EL, Woolfenden AE, et al. Identification of bronchioalveolar stem cell in normal lung and lung cancer. Cell 2005; 121: 823-35.
11. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007; 67: 1030-7.
12. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. Cancer stem cell characteristies in retinoblastoma. Mol Vis 2005; 11: 729-37.
13. Takaishi S, Okumura T, Wang TC. Gastric cancer stem cells. J Clin Oncol 2008; 26: 2876-82.
14. Weigmann A, Corbeil D, Hellwig A, Huttner WB. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci U S A 1997; 94: 12425-30.
15. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997; 90: 5002-12.
16. Miraglia S, GodfreyW,Yin AH, et al. A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood 1997; 90: 5013-21.
17. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. J Pathol 2008; 214: 3-9.
18. O'Brien CA, Pollett A, Gallinger S, Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-10.
19. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007; 445: 111-5.
20. Piccirillo SG, Reynolds BA, Zanetti N, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006; 444: 761-5.
21. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 2006; 351: 820-4.
22. Yin S, Li J, Hu C, et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007; 120: 1444-50.
23. Vercauteren SM, Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy 2001; 3: 449-59.
24. Florek M, Haase M, Marzesco AM, et al. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res 2005; 319: 15-26.
25. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117: 3539-45.
26. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest 2008; 118: 2111-20.
27. Clément V, Dutoit V, Marino D, Dietrich PY, Radovanovic I. Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer 2009; 125: 244-8.
28. Bidlingmaier S, Zhu X, Liu B. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med 2008; 86: 1025-32.
29. Shen G, Shen F, Shi Z, et al. Identification of cancer stem- like cells in the C6 glioma cell line and the limitation of current identification methods. In Vitro Cell Dev Biol Anim 2008; 44: 280-9.
30. Srivastava VK, Nalbantoglu J. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem- like phenotype. Cytometry A 2008; 73: 940-8.
31. Beier D, Hau P, Proescholdt M, et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007; 67: 4010-5.
32. Ogden AT, Waziri AE, Lochhead RA, et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008; 62: 505-15.
33. Du L, Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008; 14: 6751-60.
34. Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008; 88: 808-15.
35. Review Manager (RevMan) [Computer program]. Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
36. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327: 557-60.
37. Bexell D, Gunnarsson S, Siesjö P, Bengzon J, Darabi A. CD133+ and nestin+ tumor-initiating cells dominate in N29 and N32 experimental gliomas. Int J Cancer 2009; 125: 15-22.
38. Botchkina IL, Rowehl RA, Rivadeneira DE, et al. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis. Cancer Genomics Proteomics 2009; 6: 19-29.
39. Cammareri P, Lombardo Y, Francipane MG, Bonventre S, Todaro M, Stassi G. Isolation and culture of colon cancer stem cells. Methods Cell Biol 2008; 86: 311-24.
40. Chearwae W, Bright JJ. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer 2008; 99: 2044-53.
41. Deng YW, Fang JS, Li MC, et al. Correlation research between cancer stem cells and the pathological grades of neuroepithelial tumors. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2006; 31: 45-51.
42. Huang Q, Dong J, Zhu YD, et al. Isolation and culture of tumor stem cells from human brain glioma tissues. Zhonghua Zhong Liu Za Zhi 2006; 28: 331-3.
43. Huang Q, Zhang QB, Dong J, et al. Glioma stem cells are more aggressive in recurrent tumors with malignant progression than in the primary tumor, and both can be maintained long-term in vitro. BMC Cancer 2008; 8: 304.
44. Li MC, Deng YW, Wu J, Chen FH, Liu JF, Fang JS. Isolation and characterization of brain tumor stem cells in human medulloblastoma. Ai Zheng 2006; 25: 241-6.
45. Puglisi MA, Sgambato A, Saulnier N, et al. Isolation and characterization of CD133+ cell population within human primary and metastatic colon cancer. Eur Rev Med Pharmacol Sci 2009; 13 (Suppl 1): 55-62.
46. Wu A, Oh S, Wiesner SM, et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 2008; 17: 173-84.
47. Yi L, Zhou ZH, PingYF, et al. Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. Mod Pathol 2007; 20: 1061-8.
48. Zhou XD, Wang XY, Qu FJ, et al. Detection of cancer stem cells from the C6 glioma cell line. J Int Med Res 2009; 37: 503-10.
49. McDonald SA, Graham TA, Schier S, Wright NA, Alison MR. Stem cells and solid cancers. Virchows Arch 2009; 455: 1-13.
50. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells? J Clin Invest 2008; 118: 2021-4.
51. Tamase A, Muraguchi T, Naka K, et al. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 2009; 106: 17163-8.
52. Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, Shimizu K. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 2009; 27: 901-8.
53. Elsaba TM, Martinez-Pomares L, Robins AR, et al. The stem cell marker CD133 associates with enhanced colony formation and cell motility in colorectal cancer. PLoS One 2010; 5: e10714.
54. Fang DD, Kim YJ, Lee CN, et al. Expansion of CD133(+) colon cancer cultures retaining stem cell properties to enable cancer stem cell target discovery. Br J Cancer 2010; 102: 1265-75.
55. Kemper K, Sprick MR, de Bree M, et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010; 70: 719-29.
56. Qiang L, Yang Y, Ma YJ, et al. Isolation and characterization of cancer stem like cells in human glioblastoma cell lines. Cancer Lett 2009; 279: 13-21.
57. Todaro M, Alea MP, Di Stefano AB, et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007; 1: 389-402.
58. Haraguchi N, Ohkuma M, Sakashita H, et al. CD133+CD44+ population efficiently enriches colon cancer initiating cells. Ann Surg Oncol 2008; 15: 2927-33.
59. Beier D, Wischhusen J, Dietmaier W, et al. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol 2008; 18: 370-7.
60. Ieta K, Tanaka F, Haraguchi N, et al. Biological and genetic characteristics of tumor-initiating cells in colon cancer. Ann Surg Oncol 2008; 15: 638-48.
61. Ping YF, Yao XH, Bian XW, et al. Activation of CXCR4 in human glioma stem cells promotes tumor angiogenesis. Zhonghua Bing Li Xue Za Zhi 2007; 36: 179-83.
62. Dittfeld C, Dietrich A, Peickert S, et al. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. Radiother Oncol 2009; 92: 353-61.
63. Chen R, Nishimura MC, Bumbaca SM, et al. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 2010; 17: 362-75.
64. Tchoghandjian A, Baeza N, Colin C, et al. A2B5 cells from human glioblastoma have cancer stem cell properties. Brain Pathol 2010; 20: 211-21.
65. Ferrandina G, Petrillo M, Bonanno G, Scambia G. Targeting CD133 antigen in cancer. Expert Opin Ther Targets 2009; 13: 823-37.